REFERENCES
- Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med. 1996;2:760–766.
- Mentré F, Escolano S, Diquet B, Goldmard JL, Mallet A. Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationship to long term effi-cacy and toxicity. Eur J Clin Pharmacol. 1993;45:397–407.
- Drusano GL, Balis FM, Gitterman SR, Pizzo PA. Quantita-tive relationship between zidovudine exposure and effi-cacy and toxicity. Antimicrob Agents Chemother. 1994;38:1726–1731.
- Neumann AU, Tubiana R, Calvez V, et al., and the Comet Study Group. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. AIDS. 1999;13:677–683.
- Harker AJ, Evans GL, Hawley AE, Morris DM. High-perfor-mance liquid chromatographic assay for 2'-deoxy-3'-thiacytidine in human serum. J Chromatogr. 1994; 657:227–232.
- Unadkat JD, Crosby SS, Wang JP, Hertel CC. Simple and rapid high-performance liquid chromatography assay for zidovudine (azidothymidine) in plasma and urine. J Chromatogr. 1988;430:420–423.
- Aymard G, Legrand M, Trichereau N, Diquet B. Determina-tion of twelve antiretroviral agents in human plasma sample using reverse-phase high-performance liquid chro-matography. J Chromatogr. 2000;744(2):227–240.
- Buss N, Cammack N. Measuring the effectiveness of antiretroviral agents. Antivir Ther. 2001;6(1):1–7.
- Acosta EP, Henry K, Baken L, Page LM, Fletcher CV. Indinavir concentrations and antiviral effect. Pharmacother. 1999;19(6):708–712.
- Deluge SM, Good SS, Faletto MB, et al. 1592U89, a novel carbocyclic nucleoside analog with potent selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother. 1997;41(5):1082–1093.
- Perry CM, Faulds D. Lamivudine: a review of its antiviral activity, pharmacokinetic properties and therapeutic effi-cacy in the management of HIV infection. Drugs. 1997;53:657–680.
- Mo H, Vasavanonda S, Han L, et al. In vitro antiviral interac-tion of lopinavir with other protease inhibitors. In: Program and abstracts of the 41st ICAAC; 2001; Chicago, IL. Ab-stract 1739.
- Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and generation time. Science. 1996;271:1582–1585.
- Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123–126.
- Acosta EP, Page LM, Fletcher CV. Clinical pharmacokinet-ics of zidovudine. Clin Pharmacokinet. 1996;30:251–262.
- Hoetelmans RMW, Meenhorst PL, Mulder JW, Burger DM, Koks CHW, Beijnen JH. Clinical pharmacology of HIV pro-tease inhibitors: focus on saquinavir, indinavir, and ritonavir. Pharm World Sci. 1997;19:159–175.
- Hoetelmans RMW, Burger DM, Meenhorst PL, Beijnen JH. Pharmacokinetic individualization of zidovudine therapy. Clin Pharmacokinet. 1996;30:314–327.
- Havlir DV, Richman DD. Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann In-tern Med. 1996;124(11):984–994.
- Nelson PW, Mittler JE, Perelson AS. Effect of drug efficacy and the eclipse phase of the viral life cycle on estimates of HIV viral dynamic parameters. J Acquir Immune Defic Syndr. 2001;26(5):405–412.
- Wu H, Kuritzkes DR, McClernon DR, et al. Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virological end points. J Infect Dis. 1999;179(4):799–807.
- Wu H, Ruan P, Ding AA, Sullivan JL, Luzuriaga K. Inappro-priate model-fitting methods may lead to significant under-estimates of viral decay in HIV dynamic studies. J Acquir Immune Defic Syndr. 1999 ;21(5):426–428.
- Jackson RC. A pharmacokinetic-pharmacodynamic model of chemotherapy of human immunodeficiency virus infec-tion that relates development of drug resistance to treat-ment intensity. J Pharmacokinet Biopharm. 1997; 25(6):713–730.
- Snyder S, D'Argenio DZ, Weislow 0, Bilello JA, Drusano GL. The triple combination indinavir-zidovudine-lamivudine is highly synergistic. Antimicrob Agents Chemother. 2000;44(4):1051–1058.